

Table SI. A summary of previously reported drug eruption cases due to dupilumab			
Authors	Age/Sex	Eruption types	Treatment
Ludriksone L, et al. (1)	39 / F	Urticaria	DUP discontinued
Kim TE, et al. (2)	44 / M	Lichenoid drug eruption	DUP discontinued
Joseph AK, et al. (3)	40 / M	Urticaria	DUP continued with anti-histamine agent
Fritz AL, et al. (4)	12 / F	Angioedema	DUP discontinued
Wang M, et al. (5)	85 / M	Purpuric type drug eruption	DUP discontinued with steroid pulse therapy
Wu L, et al. (6)	17 / F	AGEP	DUP discontinued
Long XH, et al. (7)	34 / F	Erythema multiforme	DUP discontinued with steroid pulse therapy
Derbyshire M, et al. (8)	18 / F	Lichenoid drug eruption	DUP discontinued
Our case	52 / M	Multiple fixed drug eruption	DUP continued with topical steroid
DUP; dupilumab, AGEp; acute generalized exanthematous pustulosis			

References

1. Ludriksone L, Elsner P, Schliemann S. Acquired hypersensitivity to dupilumab: first case report. *J Eur Acad Dermatol Venereol.* 2019;33(12):e482-e3.
2. Kim TE, Shin MK. De novo case of lichenoid eruption following dupilumab treatment. *JAAD Case Rep.* 2021;13:71-2.
3. Joseph AK, Chong BF. Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine. *Dermatol Ther.* 2021;34(6):e15114.
4. Fritz AL, Lacy FA, Morrell DS. Angioedema: A potential complication of dupilumab in atopic dermatitis. *Pediatr Dermatol.* 2021;38(1):237-8.
5. Wang M, Zheng Q, Tang S, Shen F, Jiang W. Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab. *Acta Derm Venereol.* 2022;102:adv00744.
6. Wu L, Ali K, Qiu Y, Li M, Da J. Dupilumab-induced Acute Generalized Exanthematous Pustulosis in a 17-year-old Female Chinese Patient with Atopic Dermatitis. *Acta Derm Venereol.* 2022;102:adv00743.
7. Long XH, Jiang HS, Lai JD, Liu YH, Wang WL. Erythema multiforme-like drug eruption associated with dupilumab treatment: Report of an unusual case. *Dermatol Ther.* 2022;35(11):e15792.
8. Derbyshire M, Beatty C, Marks K, Kazlouskaya V. Lichenoid eruption during treatment of atopic dermatitis with dupilumab. *Int J Dermatol.* 2023;62(9):1202-3.